Fatty acid metabolism and vascular disease

Trends in Cardiovascular Medicine

Volumn 14, Issue 2, 2004, Pages 72-76

  Semenkovich, Clay F ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; FATTY ACID; LIPID; LIPOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; TRIACYLGLYCEROL LIPASE;

ATHEROSCLEROSIS; FATTY ACID METABOLISM; HUMAN; HYPERTENSION; INSULIN RESISTANCE; LIPID BLOOD LEVEL; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; SHORT SURVEY; VASCULAR DISEASE;

EID: 1542508935     PISSN: 10501738     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tcm.2003.12.004     Document Type: Review

References (37)

1. Andrew R., Gale C.R., Walker BRet al. Glucocorticoid metabolism and the metabolic syndrome: associations in an elderly cohort. Exp Clin Endocrinol Diabetes. 110:2002;284-290.
2. Andrews R.C., Herlihy O., Livingstone DEet al. Abnormal cortisol metabolism and tissue sensitivity to cortisol in patients with glucose intolerance. J Clin Endocrinol Metab. 87:2002;5587-5593.
3. Babaev V.R., Fazio S., Gleaves LAet al. Macrophage lipoprotein lipase promotes foam cell formation and atherosclerosis in vivo. J Clin Invest. 103:1999;1697-1705.
4. Babaev V.R., Patel M.B., Semenkovich CFet al. Macrophage lipoprotein lipase promotes foam cell formation and atherosclerosis in low density lipoprotein receptor-deficient mice. J Biol Chem. 275:2000;26,293-26,299.
5. Benthem L., Keizer K., Wiegman CHet al. Excess portal venous long-chain fatty acids induce syndrome X via HPA axis and sympathetic activation. Am J Physiol Endocrinol Metab. 279:2000;E1286-E1293.
6. Bernal-Mizrachi C., Weng S., Feng Cet al. Dexamethasone induction of hypertension and diabetes is PPARα-dependent in LDL receptor-null mice. Nat Med. 9:2003;1069-1075.
7. Brunner E.J., Hemingway H., Walker BRet al. Adrenocortical, autonomic, and inflammatory causes of the metabolic syndrome: nested case-control study. Circulation. 106:2002;2659-2665.
8. Coleman T., Seip R.L., Gimble JMet al. COOH-terminal disruption of lipoprotein lipase in mice is lethal in homozygotes, but heterozygotes have elevated triglycerides and impaired enzyme activity. J Biol Chem. 270:1995;12,518-12,525.
9. Duclos M., Gatta B., Corcuff JBet al. Fat distribution in obese women is associated with subtle alterations of the hypothalamic-pituitary-adrenal axis activity and sensitivity to glucocorticoids. Clin Endocrinol (Oxf). 55:2001;447-454.
10. Ekstrand A., Saloranta C., Ahonen Jet al. Reversal of steroid-induced insulin resistance by a nicotinic-acid derivative in man. Metabolism. 41:1992;692-697.
11. Foley J.E. Rationale and application of fatty acid oxidation inhibitors in treatment of diabetes mellitus. Diabetes Care. 15:1992;773-784.
12. Ford E.S., Giles W.H., Dietz W.H. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 287:2002;356-359.
13. Gelernter-Yaniv L., Feng N., Sebring NGet al. Associations between a polymorphism in the 11 beta hydroxysteroid dehydrogenase type I gene and body composition. Int J Obes Relat Metab Disord. 27:2003;983-986.
14. Grekin R.J., Vollmer A.P., Sider R.S. Pressor effects of portal venous oleate infusion. A proposed mechanism for obesity hypertension. Hypertension. 26:1995;193-198.
15. Guerre-Millo M., Rouault C., Poulain Pet al. PPAR-alpha-null mice are protected from high-fat diet-induced insulin resistance. Diabetes. 50:2001;2809-2814.
16. Haffner S.M., Stern M.P., Hazuda HPet al. Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA. 263:1990;2893-2898.
17. Hermanowski-Vosatka A., Gerhold D., Mundt SSet al. PPARα agonists reduce 11β-hydroxysteroid dehydrogenase type 1 in the liver. Biochem Biophys Res Commun. 279:2000;330-336.
18. Howlett T.A., Rees L.H., Besser G.M. Cushing's syndrome. Clin Endocrinol Metab. 14:1985;911-945.
19. Hu F.B., Stampfer M.J., Haffner SMet al. Elevated risk of cardiovascular diseaseprior to clinical diagnosis of type 2 diabetes. Diabetes Care. 25:2002;1129-1134.
20. Hunt K.J., Williams K., Rivera Det al. Elevated carotid artery intima-media thicknessin individuals who subsequently developtype 2 diabetes. Arterioscler Thromb Vasc Biol. 23:2003;1845-1850.
21. Kotelevtsev Y., Holmes M.C., Burchell Aet al. 11beta-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proc Natl Acad Sci USA. 94:1997;14,924-14,929.
22. Lemberger T., Staels B., Saladin Ret al. Regulation of the peroxisome proliferator-activated receptor ∀ gene by glucocorticoids. J Biol Chem. 269:1994;24,527-24,530.
23. Levak-Frank S., Radner H., Walsh Aet al. Muscle-specific overexpression of lipoprotein lipase causes a severe myopathy characterized by proliferation of mitochondria and peroxisomes in transgenic mice. J Clin Invest. 96:1995;976-986.
24. Marquez GGet al. One hundred years ofsolitude. 1st perennial classics ed. 1998;Harper Collins, New York.
25. Masuzaki H., Paterson J., Shinyama Het al. A transgenic model of visceral obesity and the metabolic syndrome. Science. 294:2001;2166-2170.
26. Masuzaki H., Yamamoto H., Kenyon CJet al. Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice. J Clin Invest. 112:2003;83-90.
27. Meinert C.L., Knatterud G.L., Prout T.E., Klimt C.R. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes. 19(Suppl):1970;789-830.
28. Orbach J., Andrews W.H. Stimulation of afferent nerve terminals in the perfused rabbit liver by sodium salts of some long-chain fatty acids. Q J Exp Physiol Cogn Med Sci. 58:1973;267-274.
29. Scharrer E. Control of food intake by fatty acid oxidation and ketogenesis. Nutrition. 15:1999;704-714.
30. Schoonjans K., Peinado-Onsurbe J., Lefebvre AMet al. PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J. 15:1996;5336-5348.
31. Semenkovich C.F., Coleman T., Daugherty A. Effects of heterozygous lipoprotein lipase deficiency on diet-induced atherosclerosis in mice. J Lipid Res. 39:1998;1141-1151.
32. Tauchmanova L., Rossi R., Biondi Bet al. Patients with subclinical Cushing's syndrome due to adrenal adenoma have increased cardiovascular risk. J Clin Endocrinol Metab. 87:2002;4872-4878.
33. Tordjman K., Bernal-Mizrachi C., Zemany Let al. PPARα deficiency reduces insulin resistance and atherosclerosis in apoE-null mice. J Clin Invest. 107:2001;1025-1034.
34. United Kingdom Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 352:1998;837-853.
35. Van Eck M., Zimmermann R., Groot PHet al. Role of macrophage-derived lipoprotein lipase in lipoprotein metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol. 20:2000;E53-E62.
36. Ward A.M., Fall C.H., Stein CEet al. Cortisol and the metabolic syndrome in South Asians. Clin Endocrinol (Oxf). 58:2003;500-505.
37. Weinstock P.H., Bisgaier C.L., Aalto-Setala Ket al. Severe hypertriglyceridemia, reduced high density lipoprotein, and neonatal death in lipoprotein lipase knockout mice. Mild hypertriglyceridemia with impaired very low density lipoprotein clearance in heterozygotes. J Clin Invest. 96:1995;2555-2568.